While the prevalence of germline BRCA1/2 PV is reported to be 10–20% in women with HGSC [12, 13], BRCA1/2 PVs are identified in 15–30% of tumor samples [14, 15, 16, 17, 18, 19]. Here, BRCA1 is linked to neoplasm.